Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.

Autor:	Pignata, Sandro1 (AUTHOR), Lorusso, Domenica2 (AUTHOR), Joly, Florence3 (AUTHOR), Gallo, Ciro4 (AUTHOR), Colombo, Nicoletta5 (AUTHOR), Sessa, Cristiana6 (AUTHOR), Bamias, Aristotelis7 (AUTHOR), Salutari, Vanda8 (AUTHOR), Selle, Frédèric9 (AUTHOR), Frezzini, Simona10 (AUTHOR), De Giorgi, Ugo11 (AUTHOR), Pautier, Patricia12 (AUTHOR), Bologna, Alessandra13 (AUTHOR), Orditura, Michele14 (AUTHOR), Dubot, Coraline15 (AUTHOR), Gadducci, Angiolo16 (AUTHOR), Mammoliti, Serafina17 (AUTHOR), Ray-Coquard, Isabelle18 (AUTHOR), Zafarana, Elena19 (AUTHOR), Breda, Enrico20 (AUTHOR)
Zdroj:	Lancet Oncology. Feb2021, Vol. 22 Issue 2, p267-276. 10p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu